Embryonic natural killer cell development and function

胚胎自然杀伤细胞的发育和功能

基本信息

  • 批准号:
    10661496
  • 负责人:
  • 金额:
    $ 57.94万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-05-01 至 2025-04-30
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY / ABSTRACT The overall goal of our research is to understand the origin, development and function of embryonic Natural Killer (NK) cells. NK cells are innate immune system lymphocytes and a current target population for cell- based adoptive immunotherapies. However, NK cell therapy has been demonstrated to be effective in only a subset of patients, possibly due in part to the highly heterogeneous nature of NK cell subsets found across donors. In contrast, the generation of NK cells from human pluripotent stem cells (hPSCs) is a particularly exciting alternative, as it would eliminate genetic variability across donor sources, ensuring highly reproducible generation of anti-tumor NK cells. While NK cells in the adult are derived from hematopoietic stem cell (HSC)- derived lymphoid progenitors, the developmental origin of NK cells remains poorly understood. We have demonstrated that HSC-independent hematopoiesis occurs in multiple waves in the early murine embryo, including multipotential “erythro-myeloid progenitors” (EMP). Similarly, we have developed an in vitro hPSC stage-specific differentiation approach that recapitulates many aspects of embryonic hematopoietic development. Combining these systems, our preliminary parallel studies indicate that HSC-independent, “extra-embryonic” erythro-myeloid progenitors can generate NK cells, which are morphologically and functionally distinct from “intra-embryonic” hPSC-derived definitive progenitors, or neonatal donors. The focus of this proposal is to bring together expertise in mouse developmental biology and hPSC directed differentiation, as complementary model systems, to identify the origin(s) of embryonic NK cells, and their translational potential. We hypothesize that these fetal NK cells are a clinically-relevant source of NK cells, with robust antitumor capacity. We will test this hypothesis across three Specific Aims. In Aim 1, we will characterize the ontogenic origins of murine embryonic and hPSC-derived NK cells, establishing their lineage specification from a multipotential myeloid progenitor and the transcriptional regulatory programs. In Aim 2, we will establish the contribution of embryonic NK cells to the adult lymphocyte repertoire, and functionally characterize the adoptive transfer antitumor potential of HSC-independent NK cells. The successful completion of these studies will provide us with a more comprehensive understanding of mammalian hematopoietic development. This is of fundamental importance to our understanding of the development of the innate immune system and the in vitro generation of NK cells for a wide array of regenerative medicine applications, including anti-cancer therapy.
项目摘要/摘要 我们研究的总体目标是了解胚胎自然的起源、发展和功能 杀伤(NK)细胞。NK细胞是先天免疫系统的淋巴细胞,目前是细胞的靶群。 以过继免疫疗法为基础。然而,NK细胞疗法已被证明只在 患者的亚群,可能部分是由于在 捐赠者。相比之下,从人类多能干细胞(HPSCs)产生NK细胞是一个特别重要的问题 令人兴奋的替代方案,因为它将消除捐赠者来源之间的遗传变异,确保高度可重复性 抗肿瘤NK细胞的产生。而成人的NK细胞来自造血干细胞(HSC)- 作为原始淋巴祖细胞,NK细胞的发育起源目前仍知之甚少。我们有 证明在小鼠早期胚胎中,HSC非依赖的造血发生在多波中, 包括多潜能的“红系祖细胞”(EMP)。同样,我们已经开发出一种体外hPSC 阶段特异性分化方法概括了胚胎造血的许多方面 发展。结合这些系统,我们的初步平行研究表明,不依赖于HSC, “胚胎外”的红系祖细胞可以产生NK细胞,在形态上和 在功能上不同于“胚胎内”hPSC衍生的最终祖细胞,或新生儿捐赠者。焦点 这项建议的目的是将小鼠发育生物学和hPSC指导的专业知识结合起来 分化作为互补模型系统用于鉴定胚胎NK细胞的来源(S)及其 翻译潜力。我们假设这些胎儿NK细胞是临床上相关的NK细胞来源, 强大的抗肿瘤能力。我们将通过三个具体目标来检验这一假设。在目标1中,我们将 鉴定小鼠胚胎和hPSC来源的NK细胞的个体起源,建立其谱系 来自多潜能髓系祖细胞的规范和转录调控程序。在目标2中,我们 将建立胚胎NK细胞对成人淋巴细胞库的贡献,并在功能上 鉴定HSC非依赖性NK细胞过继转移抗肿瘤的潜能。圆满完成 这些研究将为我们提供对哺乳动物造血的更全面的了解 发展。这对于我们理解人的先天发展是至关重要的。 免疫系统和NK细胞的体外生成,用于广泛的再生医学应用, 包括抗癌治疗。

项目成果

期刊论文数量(4)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
CD1d expression demarcates CDX4+ hemogenic mesoderm with definitive hematopoietic potential.
  • DOI:
    10.1016/j.scr.2022.102808
  • 发表时间:
    2022-07
  • 期刊:
  • 影响因子:
    1.2
  • 作者:
    Creamer, J. Philip;Luff, Stephanie A.;Yu, Hao;Sturgeon, Christopher M.
  • 通讯作者:
    Sturgeon, Christopher M.
Yolk sac cell atlas reveals multiorgan functions during human early development.
  • DOI:
    10.1126/science.add7564
  • 发表时间:
    2023-08-18
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Goh I;Botting RA;Rose A;Webb S;Engelbert J;Gitton Y;Stephenson E;Quiroga Londoño M;Mather M;Mende N;Imaz-Rosshandler I;Yang L;Horsfall D;Basurto-Lozada D;Chipampe NJ;Rook V;Lee JTH;Ton ML;Keitley D;Mazin P;Vijayabaskar MS;Hannah R;Gambardella L;Green K;Ballereau S;Inoue M;Tuck E;Lorenzi V;Kwakwa K;Alsinet C;Olabi B;Miah M;Admane C;Popescu DM;Acres M;Dixon D;Ness T;Coulthard R;Lisgo S;Henderson DJ;Dann E;Suo C;Kinston SJ;Park JE;Polanski K;Marioni J;van Dongen S;Meyer KB;de Bruijn M;Palis J;Behjati S;Laurenti E;Wilson NK;Vento-Tormo R;Chédotal A;Bayraktar O;Roberts I;Jardine L;Göttgens B;Teichmann SA;Haniffa M
  • 通讯作者:
    Haniffa M
Haematopoietic stem and progenitor cell heterogeneity is inherited from the embryonic endothelium.
  • DOI:
    10.1038/s41556-023-01187-9
  • 发表时间:
    2023-08
  • 期刊:
  • 影响因子:
    21.3
  • 作者:
  • 通讯作者:
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

James Palis其他文献

James Palis的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('James Palis', 18)}}的其他基金

Embryonic natural killer cell development and function
胚胎自然杀伤细胞的发育和功能
  • 批准号:
    10328573
  • 财政年份:
    2021
  • 资助金额:
    $ 57.94万
  • 项目类别:
Megakaryocyte and platelet ontogeny
巨核细胞和血小板个体发育
  • 批准号:
    8829970
  • 财政年份:
    2013
  • 资助金额:
    $ 57.94万
  • 项目类别:
2013 Red Cells Gordon Research Conference & Gordon Research Seminar
2013 红细胞戈登研究会议
  • 批准号:
    8525933
  • 财政年份:
    2013
  • 资助金额:
    $ 57.94万
  • 项目类别:
Megakaryocyte and platelet ontogeny
巨核细胞和血小板个体发育
  • 批准号:
    8694029
  • 财政年份:
    2013
  • 资助金额:
    $ 57.94万
  • 项目类别:
Megakaryocyte and platelet ontogeny
巨核细胞和血小板个体发育
  • 批准号:
    9043868
  • 财政年份:
    2013
  • 资助金额:
    $ 57.94万
  • 项目类别:
Megakaryocyte and platelet ontogeny
巨核细胞和血小板个体发育
  • 批准号:
    8478982
  • 财政年份:
    2013
  • 资助金额:
    $ 57.94万
  • 项目类别:
Megakaryocyte and platelet ontogeny
巨核细胞和血小板个体发育
  • 批准号:
    9264520
  • 财政年份:
    2013
  • 资助金额:
    $ 57.94万
  • 项目类别:
Role of EPO in terminal erythroid maturation
EPO 在终末红细胞成熟中的作用
  • 批准号:
    8685321
  • 财政年份:
    2012
  • 资助金额:
    $ 57.94万
  • 项目类别:
Role of EPO in terminal erythroid maturation
EPO 在终末红细胞成熟中的作用
  • 批准号:
    8875051
  • 财政年份:
    2012
  • 资助金额:
    $ 57.94万
  • 项目类别:
Role of EPO in terminal erythroid maturation
EPO 在终末红细胞成熟中的作用
  • 批准号:
    8417125
  • 财政年份:
    2012
  • 资助金额:
    $ 57.94万
  • 项目类别:

相似海外基金

Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM
ATTAC 时间:针对 gp100 细胞的 T 细胞过继转移来治疗 LAM
  • 批准号:
    10682121
  • 财政年份:
    2023
  • 资助金额:
    $ 57.94万
  • 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
  • 批准号:
    10576370
  • 财政年份:
    2022
  • 资助金额:
    $ 57.94万
  • 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
  • 批准号:
    10387023
  • 财政年份:
    2022
  • 资助金额:
    $ 57.94万
  • 项目类别:
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
  • 批准号:
    10248409
  • 财政年份:
    2019
  • 资助金额:
    $ 57.94万
  • 项目类别:
A phase I clinical study of adoptive transfer of regulatory T cells (Tregs) and low-dose interleukin-2 (IL-2) for the treatment of chronic graft-versus-host disease (GVHD): gene-marking to inform rational combination therapy
调节性 T 细胞 (Treg) 和低剂量白细胞介素 2 (IL-2) 过继转移治疗慢性移植物抗宿主病 (GVHD) 的 I 期临床研究:基因标记为合理的联合治疗提供信息
  • 批准号:
    nhmrc : GNT1163111
  • 财政年份:
    2019
  • 资助金额:
    $ 57.94万
  • 项目类别:
    Project Grants
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
  • 批准号:
    10462684
  • 财政年份:
    2019
  • 资助金额:
    $ 57.94万
  • 项目类别:
Gene edited lymphoid progenitors for adoptive transfer as a treatment of primary immunodeficiency
基因编辑的淋巴祖细胞用于过继转移作为原发性免疫缺陷的治疗
  • 批准号:
    398018062
  • 财政年份:
    2018
  • 资助金额:
    $ 57.94万
  • 项目类别:
    Research Grants
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
  • 批准号:
    9308643
  • 财政年份:
    2017
  • 资助金额:
    $ 57.94万
  • 项目类别:
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
  • 批准号:
    9447149
  • 财政年份:
    2017
  • 资助金额:
    $ 57.94万
  • 项目类别:
Targeting Cancer miRNAs by Adoptive Transfer of Programmed B Lymphocytes
通过程序化 B 淋巴细胞的过继转移靶向癌症 miRNA
  • 批准号:
    8893915
  • 财政年份:
    2014
  • 资助金额:
    $ 57.94万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了